QIAGEN (QGEN) says it's received FDA approval to market its therascreen KRAS test to provide...

|By:, SA News Editor

QIAGEN (QGEN) says it's received FDA approval to market its therascreen KRAS test to provide guidance on the use of Erbitux as a treatment in patients with metastatic colorectal cancer.